Sitagliptin Improves Glycemic Profile In Type 2 Diabetes Mild Renal Impairment | Latest News RSS feed

Sitagliptin Improves Glycemic Profile In Type 2 Diabetes Mild Renal Impairment - Latest News


Top stories in endocrinology: Experts push for transgender health priorities; pharmacotherapy effective weight-loss option

Read More. Sitagliptin improves glycemic profile in type 2 diabetes, mild renal impairment Adults with type 2 diabetes, mild renal insufficiency and an elevated HbA1c assigned the DPP-IV inhibitor sit... read more

Merck : Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)

“These studies further support the clinical profile of JANUVIA ... Safety and Efficacy of Sitagliptin Compared with Dapagliflozin in Subjects with Type 2 Diabetes, Mild Renal Impairment and Inadequate ... read more

Merck Presents New Data from the Comparative Trials with Sitagli - MSNewsNow.com - Jackson, MS

“These studies further support the clinical profile of JANUVIA ... Safety and Efficacy of Sitagliptin Compared with Dapagliflozin in Subjects with Type 2 Diabetes, Mild Renal Impairment and Inadequate ... read more

Looking for another news?


Merck Presents New Data from the Comparative Trials with Sitagli - KSWO 7News | Breaking News, Weather and Sports

“These studies further support the clinical profile of JANUVIA ... Safety and Efficacy of Sitagliptin Compared with Dapagliflozin in Subjects with Type 2 Diabetes, Mild Renal Impairment and Inadequate ... read more


Ozempic® approved in Canada for the treatment of adults with type 2 diabetes

as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, when metformin is not tolerated or contraindicated. 1 Ozempic ®, a once-weekly glucagon-like pep... read more

FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults

Dapagliflozin is being reviewed by the FDA for use as monotherapy, and in combination with other antidiabetic agents, as an adjunct to diet and exercise to improve glycemic control in adults with type ... read more

Liraglutide doesn't affect gastric emptying in type 1 diabetes

There was an increase in heart rate with liraglutide (69 ± 4 to 80 ± 5 beats/min; P = 0.02). "Liraglutide does not compromise glycemic recovery, GE rate, or counterregulatory hormone responses in type ... read more

Merck and : - Late-Breaking Data to be presented from the Comparative Trials with Sitagliptin Program on the Continuation of JANUVIA Treatment

00 p.m.) Safety and Efficacy of Sitagliptin Compared with Dapagliflozin in Subjects with Type 2 Diabetes, Mild Renal Impairment and Inadequate Glycemic Control on Metformin +/- a Sulfonylurea (Abstrac... read more

Janssen Research & Development to Present Results from Five Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

The kidneys of people with type 2 diabetes ... moderate renal impairment and inadequate glycemic control with diet and exercise, will be presented in the poster presentation “Canagliflozin, a Sodium G... read more

Ozempic® approved in Canada for the treatment of adults with type 2 diabetes

as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, when metformin is not tolerated or contraindicated. 1 Ozempic ®, a once-weekly glucagon-like pep... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us